{"id":"vyndamax-tafamidis-61mg","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT04801329"],"aliases":[],"patents":[],"pricing":[],"allNames":"vyndamax (tafamidis 61mg)","offLabel":[],"timeline":[],"aiSummary":"Vyndamax (tafamidis 61mg) is a small molecule that stabilizes transthyretin, a protein associated with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). It is used to treat Transthyretin Amyloid Cardiomyopathy, as indicated by clinical trials.","brandName":"Vyndamax (tafamidis 61mg)","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"As prescribed in real world practice","explanation":"","oneSentence":"As prescribed in real world practice","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"vyndamax-tafamidis-61mg","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","phase":"preclinical","trialId":"","patients":null,"diseaseId":"cardiovascular","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04801329","phase":"N/A","title":"Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Car","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":110,"indication":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","completionDate":"2026-12","primaryEndpoint":"This non-interventioal study will be performed by design of post-marketing surveillance (PMS) as an additional pharmacovigilance activity of the Risk Management Plan (RMP) for Vyndamax® Capsules, whic"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL2103837"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}